Genky DrugStores Co., Ltd.
Supplementary Materials for the Fiscal Year Ending June 2026 Financial Results
For the fiscal year ending June 2026, net sales were JPY 221.2 billion, up 10.2% YoY; operating income was JPY 11.05 billion, up 14.45% YoY; and net income was JPY 7.85 billion, up 11.15% YoY.
Key Figures
- Net Sales: JPY 221.2 billion (Up 10.2% YoY)
- Operating Income: JPY 11.05 billion (Up 14.45% YoY)
- Net Income: JPY 7.85 billion (Up 11.15% YoY)
AI要約
Overview of Performance
In the fiscal year ending June 2026, Genky DrugStores achieved net sales of JPY 221.2 billion (up 10.2% YoY), operating income of JPY 11.05 billion (up 14.45% YoY), and net income of JPY 7.85 billion (up 11.15% YoY). Gross profit margin remained stable at approximately 20.43%, while selling, general and administrative expenses ratio was approximately 15.44%. The number of stores increased to 538, with existing store sales maintaining positive growth YoY. The operating margin stood at approximately 5.1%, indicating a robust profitability structure.
Financial Indicators and Future Outlook
The equity ratio remained sound at 41.8%, maintaining a healthy financial base. Return on equity (ROE) was 14.2%, and return on assets (ROA) was 8.2%, reflecting efficient capital management. Cash flow from operations totaled approximately JPY 12.6 billion, with investing cash flow at approximately negative JPY 5.6 billion, resulting in free cash flow of approximately JPY 7.0 billion. Growth is being accelerated through active store openings and renovations, and stable growth is expected to continue.
